Pipeline

Oxford BioTherapeutics is Pioneering the Discovery of Novel Oncology Targets for Solid Tumours

We bring 20 years of innovation to the ADC and TCE field. In addition to our own, proprietary pipeline of ADC and TCE candidates we have a number of partnerships and collaborations that leverage our OGAP®-Verify technology.

Modalities

All

ADC

Antibody Drug Conjugate

TCE

T-cell engager

IO mAb

Immuno-Oncology Monoclonal Antibody

Partnership

All

Partnered

Internal Assets

Filter Pipeline

Discovery

Pre-Clinical

Phase I

Phase II

Phase III

OBT076

Indication

Advanced or refractory solid tumours

Modality

ADC

Target

CD205

OBT076

Clinical Collaboration

Indication

Advanced or refractory solid tumours

Modality

ADC/mAb

Target

CD205 and PD-1

OBT076

Clinical Collaboration

Indication

Adenoid cystic carcinomas of the head and neck

Modality

ADC

Target

CD205